ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
119.662,38
0,08%
S&P 500
5.431,60
-0,04%
US Dollar vs BRL
5,35049
0,00%
Bitcoin
66.460,64
0,41%
Brent Oil
82,275
0,00%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Spero Therapeutics Inc (SPRO)

  7. Spero Therapeutics Inc (SPRO) Notícias

SPRO

Spero Therapeutics (SPRO)

Spero Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:SPRO
DataHoraFonteTítuloCódigoCompanhia
03/06/202417:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SPROSpero Therapeutics Inc
30/05/202417:25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPROSpero Therapeutics Inc
15/05/202417:02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SPROSpero Therapeutics Inc
15/05/202408:50IH Market NewsU.S. Index Futures Flat Ahead of April CPI Data Release, Oil Prices DropNASDAQ:SPROSpero Therapeutics Inc
06/03/202410:05GlobeNewswire Inc.Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024NASDAQ:SPROSpero Therapeutics Inc
28/02/202410:05GlobeNewswire Inc.Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial InfectionsNASDAQ:SPROSpero Therapeutics Inc
26/02/202410:05GlobeNewswire Inc.Spero Therapeutics to Present at Cowen’s 44th Annual Healthcare ConferenceNASDAQ:SPROSpero Therapeutics Inc
05/02/202418:50Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SPROSpero Therapeutics Inc
31/01/202418:05GlobeNewswire Inc.Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:SPROSpero Therapeutics Inc
05/01/202410:05GlobeNewswire Inc.Spero Therapeutics Provides Corporate Update and 2024 OutlookNASDAQ:SPROSpero Therapeutics Inc
02/01/202410:05GlobeNewswire Inc.Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract InfectionsNASDAQ:SPROSpero Therapeutics Inc
15/11/202318:15Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SPROSpero Therapeutics Inc
13/11/202318:50Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SPROSpero Therapeutics Inc
13/11/202318:05GlobeNewswire Inc.Spero Therapeutics Announces Third Quarter 2023 Operating Results and Provides a Business UpdateNASDAQ:SPROSpero Therapeutics Inc
13/11/202308:45IH Market NewsMonday’s Wall Street Highlights: Boeing, Novo Nordisk, Moody’s, StoneCo, and moreNASDAQ:SPROSpero Therapeutics Inc
06/11/202310:05GlobeNewswire Inc.Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023NASDAQ:SPROSpero Therapeutics Inc
01/11/202317:05GlobeNewswire Inc.Spero Therapeutics to Present at Upcoming November Investor ConferencesNASDAQ:SPROSpero Therapeutics Inc
01/11/202309:05GlobeNewswire Inc.Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business OfficerNASDAQ:SPROSpero Therapeutics Inc
16/10/202317:01Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:SPROSpero Therapeutics Inc
20/09/202317:05GlobeNewswire Inc.Spero Therapeutics to Present at Cantor’s Global Healthcare 2023 Investor ConferenceNASDAQ:SPROSpero Therapeutics Inc
06/09/202309:05GlobeNewswire Inc.Spero Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:SPROSpero Therapeutics Inc
01/09/202317:11Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:SPROSpero Therapeutics Inc
01/09/202317:08Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:SPROSpero Therapeutics Inc
22/08/202318:27Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:SPROSpero Therapeutics Inc
10/08/202317:05GlobeNewswire Inc.Spero Therapeutics Announces Second Quarter 2023 Operating Results and Provides a Business UpdateNASDAQ:SPROSpero Therapeutics Inc
03/08/202309:05GlobeNewswire Inc.Spero Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023NASDAQ:SPROSpero Therapeutics Inc
31/07/202313:59Dow Jones NewsSpero Therapeutics Shares Rise 14% After Special Protocol Assessment Agreement With FDANASDAQ:SPROSpero Therapeutics Inc
31/07/202309:51Dow Jones NewsSpero Therapeutics in Special Protocol Assessment Agreement for Phase 3 Trial of Tebipenem HBrNASDAQ:SPROSpero Therapeutics Inc
31/07/202309:05GlobeNewswire Inc.Spero Therapeutics Announces Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO Trial of Tebipenem HBrNASDAQ:SPROSpero Therapeutics Inc
14/06/202309:31Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SPROSpero Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:SPRO

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
IDIV
Dividend
BOV
RRRP3
3R Petroleum Oleo E Gas ... ON
BOV
TOTS3
TOTVS ON
BOV
BPAC11
BTG PACTUAL UNT
BOV
CMIN3
CSN Mineracao S.A ON
BOV
HAGA3
HAGA ON
BOV
HOOT4
HOTEIS OTHON PN
BOV
BRBI11
BR PARTNERS UNT N2
BOV
PETR4
PETROBRAS PN
BOV
PRIO3
PETRORIO ON
BOV
RCSL3
RECRUSUL ON
BOV
VVEO3
CM Hospitalar ON
BOV
HBOR3
HELBOR ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados